SUBSCRIBE
SUBSCRIBE

Alzheon

NEWS
The Top 6 Global Generic Drug Companies to Work Fo
Drug Development
Alzheon Launches IPO to Fund Alzheimer’s Drug
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
March 19, 2018
 · 
2 min read
 · 
Mark Terry
Business
Top 20 Life Science Startups to Watch in the U.S.
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
January 26, 2016
 · 
15 min read
 · 
Mark Terry
What You Need to Know About Alzheon
Business
What You Need to Know About Alzheon
December 17, 2015
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Raising $10M in Series A, Alzheon CEO Bets He Can Beat Biogen With World’s First Alzheimer’s Drug
April 8, 2015
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2016
JOBS
IN THE PRESS
Genetown
Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference
June 7, 2022
 · 
9 min read
Drug Development
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio
April 14, 2022
 · 
8 min read
Business
Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance
April 14, 2022
 · 
9 min read
Drug Development
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences
March 8, 2022
 · 
9 min read
Drug Development
Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
February 8, 2022
 · 
11 min read
Genetown
Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022
January 5, 2022
 · 
10 min read
Drug Development
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference
November 1, 2021
 · 
11 min read
Drug Development
Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021
September 13, 2021
 · 
8 min read
Business
Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development
September 13, 2021
 · 
9 min read
Drug Development
Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease
June 23, 2021
 · 
9 min read
Load More